167 related articles for article (PubMed ID: 15863522)
1. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease.
Robinson SD; Ludlam CA; Boon NA; Newby DE
Heart; 2006 Feb; 92(2):170-6. PubMed ID: 15863522
[TBL] [Abstract][Full Text] [Related]
2. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
3. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.
Parker JD; Bart BA; Webb DJ; Koren MJ; Siegel RL; Wang H; Malhotra B; Jen F; Glue P
Crit Care Med; 2007 Aug; 35(8):1863-8. PubMed ID: 17522570
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure.
Hryniewicz K; Dimayuga C; Hudaihed A; Androne AS; Zheng H; Jankowski K; Katz SD
Clin Sci (Lond); 2005 Apr; 108(4):331-8. PubMed ID: 15574127
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans.
Dover AR; Hadoke PW; Walker BR; Newby DE
J Cardiovasc Pharmacol; 2007 Sep; 50(3):321-6. PubMed ID: 17878762
[TBL] [Abstract][Full Text] [Related]
6. Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia: effects of vitamin supplementation.
Chia S; Wilson R; Ludlam CA; Webb DJ; Flapan AD; Newby DE
Clin Sci (Lond); 2005 Jan; 108(1):65-72. PubMed ID: 15367100
[TBL] [Abstract][Full Text] [Related]
7. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
Chia S; Qadan M; Newton R; Ludlam CA; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):695-701. PubMed ID: 12692009
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients.
Attinà TM; Malatino LS; Maxwell SR; Padfield PL; Webb DJ
J Hypertens; 2008 Mar; 26(3):501-7. PubMed ID: 18300861
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
10. Erectile dysfunction in patients with coronary artery disease.
Kloner R; Padma-Nathan H
Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
[TBL] [Abstract][Full Text] [Related]
11. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men.
Dishy V; Sofowora G; Harris PA; Kandcer M; Zhan F; Wood AJ; Stein CM
Clin Pharmacol Ther; 2001 Sep; 70(3):270-9. PubMed ID: 11557915
[TBL] [Abstract][Full Text] [Related]
12. Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.
Din JN; Archer RM; Harding SA; Sarma J; Lyall K; Flapan AD; Newby DE
Heart; 2013 Feb; 99(3):168-74. PubMed ID: 23184014
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.
Thiesson HC; Jensen BL; Jespersen B; Schaffalitzky de Muckadell OB; Bistrup C; Walter S; Ottosen PD; Veje A; Skøtt O
Am J Physiol Renal Physiol; 2005 May; 288(5):F1044-52. PubMed ID: 15613622
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
15. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
Schulze-Neick I; Hartenstein P; Li J; Stiller B; Nagdyman N; Hübler M; Butrous G; Petros A; Lange P; Redington AN
Circulation; 2003 Sep; 108 Suppl 1():II167-73. PubMed ID: 12970227
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study.
Vardi Y; Appel B; Ofer Y; Greunwald I; Dayan L; Jacob G
J Urol; 2009 Dec; 182(6):2850-5. PubMed ID: 19837434
[TBL] [Abstract][Full Text] [Related]
17. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects.
Kruuse C; Thomsen LL; Jacobsen TB; Olesen J
J Cereb Blood Flow Metab; 2002 Sep; 22(9):1124-31. PubMed ID: 12218418
[TBL] [Abstract][Full Text] [Related]
18. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil extends survival and graft function in a large animal lung transplantation model.
Korom S; Hillinger S; Cardell M; Zhai W; Tan Q; Dutly A; Leskosek B; Weder W
Eur J Cardiothorac Surg; 2006 Mar; 29(3):288-93. PubMed ID: 16442298
[TBL] [Abstract][Full Text] [Related]
20. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
